Dr. Sennewald Medizintechnik GmbH was founded in 1985 by Dr. Gerhard Sennewald in Munich with the goal of discovering trendsetting electro-medical systems providing innovative and beneficial medical treatments and introducing them in Europe. From the beginning, cancer therapy was in the forefront of the company, with a focus on regional and local hyperthermia. For more information, visit www.sennewald.de.

Varian Medical Systems’ mission is to focus energy on saving lives. To meet this challenge, we equip the world with new tools for fighting cancer. Since the 1950s we have been producing tools that harness the power of X-ray energy to benefit humankind. We have a robust product portfolio, and long-standing relationships with many of the world’s leading clinicians and manufacturers of industrial and medical imaging systems. Varian is developing innovative, cost-effective solutions that help make the world a healthier, more secure place. For more information, visit www.varian.com.

Heckel is a pioneer in infrared whole-body hyperthermia (WBH) and has established a strategic partnership with Hydrosun Medizintechnik GmbH, the leading manufacturer of water-filtered infrared A radiators. The heckel-HT3000 can be used for fever-range and extreme WBH. Moreover, heckel distributes the hydrosun TWH system (Thermography-controlled Water-filtered infrared A Hyperthermia) for the treatment of superficial tumours, especially chest wall recurrence.

Celsius42+ is a German supplier of a deep region loco-regional hyperthermia device. It operates on the capacitative principle and with some advanced technological features is capable of achieving sufficient temperature gradients in the depth of a body. In vivo real temperature measurements have proved this claim. Marketing started only six years ago and by now Celsius42+ has already become widespreadly known with customers in many European countries, Canada, Middle America, South East Asia, India, the Far East and Australia.

Oncotherm develops and manufactures cancer treatment systems using a special kind of hyperthermia (Oncothermia) that combines heat and an electrical field and is applied as complementary treatment to chemo- and radiotherapy. The method can be used for all tumor types and stages. Treatment goals are the extension of the survival time, improvement of the quality of life and minimization of the side effects of chemo- and radiotherapy.

The SYNCHROTHERM brand produces Hyperthermia equipments since the late eighties. SYNCHROTHERM equipments acquired in 2004, by IRCC in Candiolo-Italy, the Characterization as a “system for deep oncological hyperthermia”, according to the main guidelines given by ESHO. SYNCHROTHERM systems use a frequency emission of 13,56 MHz, the capacitive system is highly effective in treating deep localized tumours, it is possible to localize the heat concentration, according to the depth of cancer mass and the thickness of the patient. The special cooling system applied to flexible emitting radiofrequency electrodes has been designed and regularly patented in 1988.

ZMT Zurich Medtech AG is committed to developing and providing advanced, user-friendly, and comprehensively validated computational simulation tools and dedicated high-quality evaluation and test systems for accelerating research on improving human health and quality of life, shortening product development cycles, and reducing time and costs to achieve regulatory compliance. Our product Sim4Life is the first simulation platform centered on computable human phantoms (multiphysics, multiscale, tissue) for BioMed and Life Sciences applications in complex anatomies. ZMT collaborates with many leading groups at universities in Switzerland, Europe, USA, and Asia that specialize in the development and implementation of advanced in silico methods.

Nanotherics are the market leader in products for nanoparticle heating and hyperthermia studies utilizing AC magnetic fields. The magneTherm™ system is a totally unique, very competitively priced bench top device which enables magnetic fluid and nanoparticle hyperthermia testing. It operates at a wide range of user-configurable frequencies and field strengths in one system with no hidden extras needed. The magneTherm™ allows users to study magnetic nanoparticle heating effects calorimetrically, in-vitro and in-vivo. The magneTherm™ offers internal/external solenoid/pancake coils, options for water jackets (in vivo) plus capabilities to expose cells to AMF on a microscope stage for time lapse studies.

PROVIDING EARLY ACCESS TO DRUGS IN DEVELOPMENT - myTomorrows provides physicians and patients that are excluded from clinical trials with access to drugs in development. We focus on disease areas with unmet needs; oncology, neurology, psychiatry and rare diseases. myTomorrows identifies drugs in development, informs physicians and patients and facilitates requests for access to these drugs in development.

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead drug is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently being evaluated in recurrent chest wall disease breast cancer and primary liver cancer indications. The pipeline also includes EGEN-001, a DNA-based immunotherapy for localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlasTM and TheraSilenceTM. For more information, visit Celsion’s website.

ALBA is a project born in 1995 with the purpose of expanding the clinical use of Hyperthermia to different medical spheres. After more than 20 years of research and development in collaboration with top international university cancer centers, today ALBA 4000 and ALBA 4D represent the latest technology in superficial and deep Hyperthermia. Leader in the field of RF signal generation, amplification and control, the ALBA technology platform is always in development to bring Hyperthermia to the highest clinical standard required by the association with radio and chemotherapy. Please visit our website.

The Andromedic Italy was founded in 1994 by the entrepreneurial initiative of a group of experts from companies operating in the health sector. It is now well established in its field. Andromedic Srl has been on the healthcare market for many years with a team of staff with diverse skills and specialized based on the context of the client organization and technology. We combine quality, reliability, competence and professionalism, flexibility and speed in responding to customer needs. The product of Andromedic's hyperthermia department, HY-DEEP 600WM, has characteristics of quality and innovation that make it a unique device in deep hyperthermia market.